Peptides w/ Dr. Kyle Gillett, Doug Larson, Coach Travis Mash and Dr. Mike Lane #852

The episode dives deep into the rapidly evolving world of peptides, separating science from hype with candid insights from Dr. Kyle Gillette. Contrary to popular belief, most peptides like BPC-157 have minimal human clinical trials—only two completed, several ongoing—but are still widely used in performance and recovery circles. Dr. Gillette warns that while BPC-157 promotes angiogenesis and tissue repair, its systemic effects raise legitimate concerns about fueling undetected tumors, especially in those with a history of cancer or incidental angiomas. He challenges the notion that BPC-157 is 'safe' simply because it's natural, emphasizing that bioidentical doesn't mean risk-free. The discussion shifts to GLP-1s like semaglutide and the newer triple agonist retatrutide, with Dr. Gillette cautioning that retatrutide’s superiority over high-dose semaglutide is likely overstated due to selection bias—early adopters are already highly motivated and health-conscious. He predicts a future of multi-agonist peptides (quintuple agonists) that could revolutionize metabolic and musculoskeletal health, but stresses that these will be expensive and difficult to access. On cognition and performance, he dismisses most nootropics as underwhelming, favoring sleep optimization and mitochondrial support over synthetic peptides.